Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATB-320 in progressive or metastatic solid tumors
NCT06933524Phase 1Not yet recruiting
- Sponsor
- Autotelic Bio
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
01
Overview
Phase 1, open-label, single-arm trial of ATB-320 in solid tumor, sponsored by Autotelic Bio. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ATB-320
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06933524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06933524.